We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Highlights Cutting-Edge '3 Ct' PCR Assay at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: Allplex HPV HR/28 Detection test is the new frontier for high multiplex HPV screening (Photo courtesy of Seegene)
Image: Allplex HPV HR/28 Detection test is the new frontier for high multiplex HPV screening (Photo courtesy of Seegene)

Seegene, Inc. (Seoul, Korea) is presenting Allplex HPV HR Detection, a PCR assay that applies the company’s leading-edge proprietary '3 Ct' technology, at Medlab Middle East 2023.

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target). Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel. But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity. The successful development is based on Seegene's 20-year expertise and combines 19 different patented technologies, including DPO, TOCE, and MuDT. Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.

The Allplex HPV HR Detection being highlighted at Medlab Middle East 2023 is the world's first commercialized PCR assay applying '3 Ct' technology which has been dubbed the "dream MDx technology." It is designed to detect 14 high-risk human papillomavirus (HPV) types that can cause cervical cancer. It also provides the individual Ct value of each of the types allowing quantitative analysis regarding infection level. Early detection of HPV contributes to the prevention and management of cervical cancer. HPV products from other industry players provide individual Ct values for two high-risk types, HPV 16 and 18. The Allplex HPV HR Detection offers a significant cost advantage compared to existing HPV products and increases accessibility to PCR testing, which had been difficult previously due to high costs. The product is compatible with Seegene's fully automated AIOS (all-in-one system) which is also being highlighted at Medlab Middle East 2023.

Related Links:
Seegene, Inc. 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
C-Peptide ELISA
NovaLisa C-Peptide ELISA

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.